Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPROCAINE HYDROCHLORIDE versus SCANDONEST PLAIN.
Head-to-head clinical analysis: CHLOROPROCAINE HYDROCHLORIDE versus SCANDONEST PLAIN.
CHLOROPROCAINE HYDROCHLORIDE vs SCANDONEST PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks voltage-gated sodium channels in nerve cell membranes, inhibiting conduction of nerve impulses. Exhibits rapid onset and short duration due to hydrolysis by plasma pseudocholinesterase.
Scandonest Plain (mepivacaine) is an amide-type local anesthetic that stabilizes neuronal membranes by binding to voltage-gated sodium channels, inhibiting sodium influx and blocking nerve impulse conduction.
10-30 mL of 1% solution infiltrated locally; epidural: 15-25 mL of 2% or 3% solution, repeated as needed, not to exceed 800 mg total dose.
Dental infiltration: 1-2 mL (20-40 mg mepivacaine). Nerve block: 2-4 mL (40-80 mg). Max dose: 400 mg (approx 7 mg/kg). Do not repeat within 2 hours.
None Documented
None Documented
Terminal elimination half-life of chloroprocaine is approximately 0.1-0.2 hours (6-12 minutes) in adults with normal pseudocholinesterase activity. This extremely short half-life accounts for its rapid clearance and short duration of action.
Terminal elimination half-life: 1.9–3.2 hours in healthy adults; prolonged to 6–8 hours in hepatic impairment or severe renal disease; clinically meaningful for redosing intervals.
Primarily renal excretion of metabolites; unchanged drug undergoes rapid hydrolysis by plasma pseudocholinesterase, producing 2-chloro-4-aminobenzoic acid and diethylaminoethanol. Less than 2% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Renal excretion of unchanged drug and metabolites accounts for >95% of elimination; approximately 80% as unchanged mepivacaine and 15% as N-demethylated metabolites; biliary/fecal excretion minimal (<5%).
Category C
Category C
Local Anesthetic
Local Anesthetic